BLAINE HOLLINGER
Allopathic & Osteopathic Physicians|Internal Medicine|Gastroenterology HOUSTON, TX NPI 1124197488
Browse related groups: Allopathic & Osteopathic Physicians|Internal Medicine|Gastroenterology TX Gilead Sciences, Inc. All categories
General Payments — all program years on this page
$55,950.32
- Category: General Payments
- Program years: PY2020–2024
- Record count: 10
- As of (CMS publication): 2026-01-23
Latest program year (PY2024): $45,433.03 across 8 records · disputed records: 0
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How this figure is calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
Latest program year (PY2024) · sorted by reported total.
| Nature of payment | Amount | Records |
|---|---|---|
| Consulting Fee | $45,067.20 | 3 |
| Food and Beverage | $365.83 | 5 |
By paying entity
Latest program year (PY2024) · sorted by reported total.
| Paying entity | Amount | Records |
|---|---|---|
| Gilead Sciences, Inc. | $15,676.54 | 2 |
| Ipsen Bioscience Inc | $15,637.20 | 1 |
| Acerta Pharma LLC | $13,875.00 | 1 |
| Cook Medical LLC | $203.99 | 2 |
| Takeda Pharmaceuticals U.S.A., Inc. | $20.50 | 1 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | $19.80 | 1 |
By program year
Records — PY2024 (8)
| Record ID | Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Source |
|---|---|---|---|---|---|---|---|
| 1067524382 | Ipsen Bioscience Inc. | $15,637.20 | 02/02/2024 | Consulting Fee | Undisputed | 01/23/2026 | View at CMS |
| 1105690643 | AstraZeneca Pharmaceuticals LP | $13,875.00 | 11/09/2024 | Consulting Fee | Undisputed | 01/23/2026 | View at CMS |
| 1118337001 | Cook Medical LLC | $80.86 | 06/26/2024 | Food and Beverage | Undisputed | 01/23/2026 | View at CMS |
| 1118338001 | Cook Medical LLC | $123.13 | 05/13/2024 | Food and Beverage | Undisputed | 01/23/2026 | View at CMS |
| 1133599151 | Gilead Sciences, Inc. | $15,555.00 | 04/25/2024 | Consulting Fee | Undisputed | 01/23/2026 | View at CMS |
| 1133786937 | Gilead Sciences, Inc. | $121.54 | 10/22/2024 | Food and Beverage | Undisputed | 01/23/2026 | View at CMS |
| 1137578194 | Takeda Pharmaceuticals U.S.A., Inc. | $20.50 | 01/11/2024 | Food and Beverage | Undisputed | 01/23/2026 | View at CMS |
| 1153540082 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $19.80 | 10/16/2024 | Food and Beverage | Undisputed | 01/23/2026 | View at CMS |
Provenance & corrections
- Dataset: CMS Open Payments — General Payments
- Source: CMS Open Payments dataset (bulk file)
- Publisher of source data: Centers for Medicare & Medicaid Services
- Generated from: OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.